Otsuka Pharmaceutical Company, Limited

Kyosuke Masaki

Seiichi Shimizu

Shigeto Uchiyama

Tomomi Ueno

Megumi Kumemura

Kiyoko Imaizumi

Toshiaki Matsumoto

Akihisa Takaichi

Toshihiko Okamoto

Masamichi Toba

Takuma Imada

Tsuneyuki Noda

Hirofumi Ueno

Hideaki Koli

This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly women for which no effective means of prevention or alleviation has heretofore been available.

Isoflavone-containing composition

Microbial method of making equol-containing composition and product made

This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly woman for which no effective means of prevention or alleviation has heretofore been available.

Streptococcus and isoflavone-containing composition

A method of inhibiting liver fat accumulation which comprises administering a conjugated linoleic acid homolog to a mammal or making the mammal ingest it; and a liver fat accumulation inhibitory composition characterized by containing an effective amount of a conjugated linoleic acid homolog together with a support for medicinal preparations or foods. The administration or ingestion of CLA inhibits the total lipid content and the triglyceride content in the liver from increasing, and hence can effectively prevent diseases attributable to fatty liver, such as chronic hepatitis and hepatic cirrhosis.

Liver fat accumulation inhibitory composition, food additive for liver fat accumulation, inhibition, and method of inhibiting liver fat accumulation

This invention provides a magnesium-added potassium-supplementing pharmaceutical composition containing 3 to 15 wt. %, as K, of a potassium-containing compound and 0.2 to 5 wt. %, as Mg, of a magnesium-containing compound in a K/Mg weight ratio of 20:1 through 1:1, and particularly a magnesium-added potassium-supplementing pharmaceutical composition in an effervescent dosage form which contains the above-mentioned ingredients, in the indicated ratio, in combination with 7 to 20 percent by weight of a blowing agent and 15 to 60 percent by weight of a neutralizing agent.

Pharmaceutical composition for potassium supplementation

Growing community of inventors

Kurume, Japan

Kyosuke Masaki